Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. MDXH
stocks logo

MDXH

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
30.55M
+23.73%
-0.126
-10%
31.70M
+30.9%
-0.098
-48.68%
32.71M
+22.99%
-0.085
-39.29%
Estimates Revision
The market is revising Downward the revenue expectations for MDxHealth SA (MDXH) for FY2025, with the revenue forecasts being adjusted by -1.26% over the past three months. During the same period, the stock price has changed by 3.12%.
Revenue Estimates for FY2025
Revise Downward
down Image
-1.26%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+14.29%
In Past 3 Month
Stock Price
Go Up
up Image
+3.12%
In Past 3 Month
Wall Street analysts forecast MDXH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDXH is 7.67 USD with a low forecast of 7.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast MDXH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDXH is 7.67 USD with a low forecast of 7.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.640
sliders
Low
7.00
Averages
7.67
High
9.00
Current: 3.640
sliders
Low
7.00
Averages
7.67
High
9.00
BTIG
Buy
maintain
$6 -> $7
2025-11-13
Reason
BTIG
Price Target
$6 -> $7
2025-11-13
maintain
Buy
Reason
BTIG raised the firm's price target on MDxHealth to $7 from $6 and keeps a Buy rating on the shares. The company drove a big uplift in its liquid-based test volumes in Q3 in part due to strength from its Resolve test and new contribution from its recently acquired ExoDx test, which the company recently acquired from Bio-Techne, the analyst tells investors in a research note. MDxHealth's reported Q3 was also highlighted by robust volume growth, the firm added.
TD Cowen
Buy
upgrade
$5 -> $7
2025-11-13
Reason
TD Cowen
Price Target
$5 -> $7
2025-11-13
upgrade
Buy
Reason
TD Cowen raised the firm's price target on MDxHealth to $7 from $5 and keeps a Buy rating on the shares. The firm said 3Q sales were just shy of consensus with margins/EBITDA better. 2026 should see accelerating sales growth as ExoDx integration takes full effect, which combined with OpEx control will enable expanding positive EBITDA, supporting a favorable view on the shares.
Lake Street
Buy
upgrade
$7 -> $9
2025-11-13
Reason
Lake Street
Price Target
$7 -> $9
2025-11-13
upgrade
Buy
Reason
Lake Street raised the firm's price target on MDxHealth to $9 from $7 and keeps a Buy rating on the shares. Following the Q3 report, the firm is increasing its price target to reflect the improved profile of the company's portfolio and revenue growth prospects in 2026, the analyst tells investors.
Craig-Hallum
NULL -> Buy
initiated
$8
2025-07-17
Reason
Craig-Hallum
Price Target
$8
2025-07-17
initiated
NULL -> Buy
Reason
Craig-Hallum initiated coverage of MDxHealth with a Buy rating and $8 price target.
Craig-Hallum
William Bonello
initiated
$8
2025-07-17
Reason
Craig-Hallum
William Bonello
Price Target
$8
2025-07-17
initiated
Reason
As previously reported, Craig-Hallum analyst William Bonello initiated coverage of MDxHealth with a Buy rating and $8 price target. The firm notes MDxHealth has the only test to evaluate the risk of undetected cancer in men with a negative biopsy. It also has a test to determine whether men classified as having low-risk cancer actually have more aggressive cancer that needs to be treated. The first test has a $500M TAM that is less than 10% penetrated, and the second test has a $600M TAM that is just 40% penetrated. Craig-Hallum is looking for 20%-plus topline growth with EBITDA breakeven this quarter, with the potential for mid-teens margins in a couple of years. The company has beaten top-line estimates in each of the past nine quarters, and also trades at less than 2-times this year's revenue - which is a steep discount to the group.
See All Ratings

Valuation Metrics

The current forward P/E ratio for MDxHealth SA (MDXH.O) is -9.68, compared to its 5-year average forward P/E of -4.42. For a more detailed relative valuation and DCF analysis to assess MDxHealth SA 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.42
Current PE
-9.68
Overvalued PE
-1.51
Undervalued PE
-7.33

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-14.97
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
40.57
Undervalued EV/EBITDA
-70.51

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.19
Current PS
0.00
Overvalued PS
2.13
Undervalued PS
0.25
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

MDXH News & Events

Events Timeline

(ET)
2025-11-12
16:26:05
MDxHealth projects FY25 revenue between $108M and $110M, surpassing consensus estimate of $94.05M
select
2025-11-12
16:24:47
MDxHealth Announces Q3 Earnings Per Share of 16 Cents, Exceeding Consensus Estimate of 12 Cents
select
2025-08-05 (ET)
2025-08-05
16:40:19
Bio-Techne to divest Exosome Diagnostics business to Mdxhealth
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
6.0
11-13Benzinga
BTIG Reaffirms Buy Rating on MDxHealth, Increases Price Target to $7

  • Real-time Intelligence: Benzinga Pro offers traders the fastest news alerts to stay updated on market movements.

  • Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.

  • Market Winning Tools: The platform provides essential tools and information that help traders succeed in the stock market.

[object Object]
Preview
8.5
09-21Yahoo Finance
MDxHealth Finalizes Acquisition of Bio Techne's ExoDx to Enhance Precision Diagnostics

  • Acquisition Announcement: MDxHealth SA has completed the acquisition of Bio-Techne Corporation’s ExoDx business for $15 million, enhancing its precision diagnostics portfolio, particularly in prostate cancer testing.

  • Investment Potential: While MDxHealth is considered a strong penny stock investment, there are suggestions that certain AI stocks may offer better upside potential and lower risk.

[object Object]
Preview
7.0
01-13Business Insider
MDxHealth Q4 Preliminary Revenue Climbs; Initiates 2025 Revenue Outlook

  • Fourth Quarter and Full-Year Revenue Expectations: MDxHealth SA anticipates fourth quarter revenue of approximately $24.7 million, a 28% increase from last year, and projects full-year 2024 revenue of $90 million, also up 28%. For 2025, the company expects revenue between $108 million to $110 million, reflecting a growth of 20% to 22%.

  • CEO's Confidence and Upcoming Earnings Report: CEO Michael K. McGarrity expressed confidence in sustainable growth due to a strong sales channel and expanded offerings for urology customers. The company's annual earnings report is scheduled for release on February 26.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is MDxHealth SA (MDXH) stock price today?

The current price of MDXH is 3.64 USD — it has increased 2.54 % in the last trading day.

arrow icon

What is MDxHealth SA (MDXH)'s business?

MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.

arrow icon

What is the price predicton of MDXH Stock?

Wall Street analysts forecast MDXH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDXH is 7.67 USD with a low forecast of 7.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is MDxHealth SA (MDXH)'s revenue for the last quarter?

MDxHealth SA revenue for the last quarter amounts to NaN USD, decreased % YoY.

arrow icon

What is MDxHealth SA (MDXH)'s earnings per share (EPS) for the last quarter?

MDxHealth SA. EPS for the last quarter amounts to USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for MDxHealth SA (MDXH)'s fundamentals?

The market is revising Downward the revenue expectations for MDxHealth SA (MDXH) for FY2025, with the revenue forecasts being adjusted by -1.26% over the past three months. During the same period, the stock price has changed by 3.12%.
arrow icon

How many employees does MDxHealth SA (MDXH). have?

MDxHealth SA (MDXH) has 312 emplpoyees as of December 05 2025.

arrow icon

What is MDxHealth SA (MDXH) market cap?

Today MDXH has the market capitalization of 180.17M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free